retatrutide phase 2 trial obesity nejm 2023 triple agonist Research Guide: What the Data Reported (2026) Retatrutide, a TRIPLE agonist (GLP1,
Description
M., Lehto, S., Ronnemaa, T., Pyorala, K
If an area needs further testing, a biopsy will be taken
Holistic support services will be critical to successful long-term outcomes
Its current status is that of a powerful experimental therapy in advanced trials
[DOI] [PMC free article] [PubMed] [Google Scholar] 8.Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
